Drugs / 5 mg orally (PO) twice daily (BID) on each day
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01204710 Background | Oct 2010 → Sep 2012 | prostate cancer | Eli Lilly and Company | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5 mg orally (PO) twice daily (BID) on each day | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01204710 ↗ |
| Route | Oral | “5 mg orally (PO) twice daily (BID) on each day” NCT01204710 ↗ |